Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: A better response in male patients

Hideto Kameda, Koichi Amano, Naoya Sekiguchi, Hirofumi Takei, Hiroe Ogawa, Hayato Nagasawa, Tsutomu Takeuchi

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Methotrexate (MTX) is the most commonly used disease-modifying antirheumatic drug (DMARD) throughout the world. In Japan, MTX is recommended by the Japanese Ministry of Health, Labour, and Welfare to be given as the second or third DMARD and at a dosage of no more than 8 mg/week. We analyzed the efficacy of MTX in Japanese patients with RA in order to determine whether it is comparable to that in Western countries, where 15-20 mg/week of MTX is used, as well as to elucidate the factors associated with the favorable response to MTX. Around 8 mg/week of MTX was effective in half of the RA patients in the current study, and male sex was the only factor associated with a good response to MTX from a multivariate regression model analysis. Some of the patients who had a poor response to MTX showed an improvement with the addition of bucillamine or prednisolone. For the remaining patients, an increase in the MTX dosage to more than 8 mg/week or the use of biologics such as the anti-tumor necrosis factor (TNF)-α monoclonal antibody may be required.

Original languageEnglish
Pages (from-to)442-446
Number of pages5
JournalModern Rheumatology
Volume14
Issue number6
DOIs
Publication statusPublished - 2004 Dec
Externally publishedYes

Fingerprint

Methotrexate
Rheumatoid Arthritis
Antirheumatic Agents
Therapeutics
Prednisolone
Biological Products
Japan
Tumor Necrosis Factor-alpha
Monoclonal Antibodies
Regression Analysis
Health

Keywords

  • Bucillamine
  • Disease-modifying antirheumatic drug (DMARD)
  • Methotrexate (MTX)
  • Outcome
  • Remission

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis : A better response in male patients. / Kameda, Hideto; Amano, Koichi; Sekiguchi, Naoya; Takei, Hirofumi; Ogawa, Hiroe; Nagasawa, Hayato; Takeuchi, Tsutomu.

In: Modern Rheumatology, Vol. 14, No. 6, 12.2004, p. 442-446.

Research output: Contribution to journalArticle

Kameda, Hideto ; Amano, Koichi ; Sekiguchi, Naoya ; Takei, Hirofumi ; Ogawa, Hiroe ; Nagasawa, Hayato ; Takeuchi, Tsutomu. / Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis : A better response in male patients. In: Modern Rheumatology. 2004 ; Vol. 14, No. 6. pp. 442-446.
@article{8e268b4a1c4f438384d407bc5bf71e06,
title = "Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: A better response in male patients",
abstract = "Methotrexate (MTX) is the most commonly used disease-modifying antirheumatic drug (DMARD) throughout the world. In Japan, MTX is recommended by the Japanese Ministry of Health, Labour, and Welfare to be given as the second or third DMARD and at a dosage of no more than 8 mg/week. We analyzed the efficacy of MTX in Japanese patients with RA in order to determine whether it is comparable to that in Western countries, where 15-20 mg/week of MTX is used, as well as to elucidate the factors associated with the favorable response to MTX. Around 8 mg/week of MTX was effective in half of the RA patients in the current study, and male sex was the only factor associated with a good response to MTX from a multivariate regression model analysis. Some of the patients who had a poor response to MTX showed an improvement with the addition of bucillamine or prednisolone. For the remaining patients, an increase in the MTX dosage to more than 8 mg/week or the use of biologics such as the anti-tumor necrosis factor (TNF)-α monoclonal antibody may be required.",
keywords = "Bucillamine, Disease-modifying antirheumatic drug (DMARD), Methotrexate (MTX), Outcome, Remission",
author = "Hideto Kameda and Koichi Amano and Naoya Sekiguchi and Hirofumi Takei and Hiroe Ogawa and Hayato Nagasawa and Tsutomu Takeuchi",
year = "2004",
month = "12",
doi = "10.1007/s10165-004-0340-3",
language = "English",
volume = "14",
pages = "442--446",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "6",

}

TY - JOUR

T1 - Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis

T2 - A better response in male patients

AU - Kameda, Hideto

AU - Amano, Koichi

AU - Sekiguchi, Naoya

AU - Takei, Hirofumi

AU - Ogawa, Hiroe

AU - Nagasawa, Hayato

AU - Takeuchi, Tsutomu

PY - 2004/12

Y1 - 2004/12

N2 - Methotrexate (MTX) is the most commonly used disease-modifying antirheumatic drug (DMARD) throughout the world. In Japan, MTX is recommended by the Japanese Ministry of Health, Labour, and Welfare to be given as the second or third DMARD and at a dosage of no more than 8 mg/week. We analyzed the efficacy of MTX in Japanese patients with RA in order to determine whether it is comparable to that in Western countries, where 15-20 mg/week of MTX is used, as well as to elucidate the factors associated with the favorable response to MTX. Around 8 mg/week of MTX was effective in half of the RA patients in the current study, and male sex was the only factor associated with a good response to MTX from a multivariate regression model analysis. Some of the patients who had a poor response to MTX showed an improvement with the addition of bucillamine or prednisolone. For the remaining patients, an increase in the MTX dosage to more than 8 mg/week or the use of biologics such as the anti-tumor necrosis factor (TNF)-α monoclonal antibody may be required.

AB - Methotrexate (MTX) is the most commonly used disease-modifying antirheumatic drug (DMARD) throughout the world. In Japan, MTX is recommended by the Japanese Ministry of Health, Labour, and Welfare to be given as the second or third DMARD and at a dosage of no more than 8 mg/week. We analyzed the efficacy of MTX in Japanese patients with RA in order to determine whether it is comparable to that in Western countries, where 15-20 mg/week of MTX is used, as well as to elucidate the factors associated with the favorable response to MTX. Around 8 mg/week of MTX was effective in half of the RA patients in the current study, and male sex was the only factor associated with a good response to MTX from a multivariate regression model analysis. Some of the patients who had a poor response to MTX showed an improvement with the addition of bucillamine or prednisolone. For the remaining patients, an increase in the MTX dosage to more than 8 mg/week or the use of biologics such as the anti-tumor necrosis factor (TNF)-α monoclonal antibody may be required.

KW - Bucillamine

KW - Disease-modifying antirheumatic drug (DMARD)

KW - Methotrexate (MTX)

KW - Outcome

KW - Remission

UR - http://www.scopus.com/inward/record.url?scp=11144276683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144276683&partnerID=8YFLogxK

U2 - 10.1007/s10165-004-0340-3

DO - 10.1007/s10165-004-0340-3

M3 - Article

AN - SCOPUS:11144276683

VL - 14

SP - 442

EP - 446

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 6

ER -